MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MTVA MetaVia Inc

Closed 05-08 16:00:00 EDT

1.09

-0.24

-18.05%

盘后1.12

+0.03+2.75%

19:55 EDT

High1.33	Low1.00	Vol483.95K
Open1.28	D1 Closing1.33	Amplitude24.81%
Mkt Cap5.63M	Tradable Cap3.61M	Total Shares5.16M
T/O553.26K	T/O Rate14.61%	Tradable Shares3.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":1.09,"timestamp":1778270400000,"preClose":1.33,"halted":0,"volume":483953,"hourTrading":{"tag":"盘后","latestPrice":1.12,"preClose":1.09,"latestTime":"19:55 EDT","volume":3761,"amount":4227.5578,"timestamp":1778284510540,"change":0.03,"changeRate":0.027523,"amplitude":0.055046},"delay":0,"changeRate":-0.18045112781954886,"floatShares":3313200,"shares":5164400,"eps":-7.349999,"marketStatus":"Closed","change":-0.24,"latestTime":"05-08 16:00:00 EDT","open":1.28,"high":1.33,"low":1,"amount":553264.8454506,"amplitude":0.24812,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-7.349999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1778486400000},"marketStatusCode":5,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":1.33,"preHourTrading":{"tag":"盘前","latestPrice":1.29,"preClose":1.33,"latestTime":"09:29 EDT","volume":20593,"amount":26854.0977793,"timestamp":1778246999999,"change":-0.04,"changeRate":-0.030075,"amplitude":0.090226},"postHourTrading":{"tag":"盘后","latestPrice":1.12,"preClose":1.09,"latestTime":"19:55 EDT","volume":3761,"amount":4227.5578,"timestamp":1778284510540,"change":0.03,"changeRate":0.027523,"amplitude":0.055046},"volumeRatio":6.170005},"requestUrl":"/m/hq/s/MTVA/tweets","defaultTab":"tweets","newsList":[{"id":"2634965498","title":"MetaVia Inc  expected to post a loss of 74 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634965498","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634965498?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:57","pubTimestamp":1778281026,"startTime":"0","endTime":"0","summary":"MetaVia Inc  expected to post a loss of74cents a share - Earnings Preview MetaVia Inc MTVA.OQ MTVA.O is expected to  show no change in quarterly revenue when it reports  results on May 12 (estimated) ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2VB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237901","title":"MetaVia announces annual shareholder meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237901","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237901?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:02","pubTimestamp":1776283374,"startTime":"0","endTime":"0","summary":"MetaVia schedules virtual annual stockholder meeting for June 8, 2026.Vote set on election of two Class I directors to three-year terms ending at 2029 annual meeting.Ballot includes ratification of BDO USA as independent registered public accounting firm for fiscal 2026.Stockholders to consider reverse stock split within 1-for-5 to 1-for-22 range.Additional items include increasing 2022 Equity Incentive Plan share pool by 200,000 shares, with possible adjournment to seek more votes on reverse split or equity plan amendment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL7bTQ3f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626190668","title":"MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726","url":"https://stock-news.laohu8.com/highlight/detail?id=2626190668","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626190668?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:36","pubTimestamp":1775824584,"startTime":"0","endTime":"0","summary":"MetaVia (MTVA) announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodul...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/metavia-says-first-patient-dosed-in-part-3-of-phase-1-trial-of-da-1726-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/metavia-says-first-patient-dosed-in-part-3-of-phase-1-trial-of-da-1726-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626903771","title":"MetaVia doses first patient in higher-dose Phase 1 trial of obesity drug DA-1726","url":"https://stock-news.laohu8.com/highlight/detail?id=2626903771","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626903771?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:32","pubTimestamp":1775824337,"startTime":"0","endTime":"0","summary":"MetaVia dosed first patient in higher-dose Phase 1 study Part 3 for DA-1726, its dual GLP-1 and glucagon agonist for obesity.Program targets faster escalation to higher doses to improve tolerability, positioning drug for a more streamlined dosing path versus marketed options.Earlier Phase 1 data were already presented, showing meaningful weight loss and broader metabolic improvements without detailing technical measures.New results will be presented in fourth quarter 2026.Study plans to enroll 40 obese, otherwise healthy adults across two 16-week titration cohorts.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL42mxM8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626388190","title":"Metavia Inc - Data From Phase 1 Part 3 Trial Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2626388190","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626388190?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:30","pubTimestamp":1775824200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nTUA5DDSKD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626197074","title":"Metavia Doses the First Patient in Higher-Dose Phase 1 Study of Da-1726, Its Glp-1 and Glucagon Dual Agonist for the Treatment of Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2626197074","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626197074?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:30","pubTimestamp":1775824200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nTUA5DDSKD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624482545","title":"MetaVia (MTVA): Differentiated Dual-Agonist Obesity Therapy and Solid Cash Runway Underpin Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2624482545","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624482545?lang=en_us&edition=fundamental","pubTime":"2026-04-02 00:45","pubTimestamp":1775061923,"startTime":"0","endTime":"0","summary":"MetaVia, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/metavia-mtva-differentiated-dual-agonist-obesity-therapy-and-solid-cash-runway-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/metavia-mtva-differentiated-dual-agonist-obesity-therapy-and-solid-cash-runway-underpin-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622879165","title":"MetaVia Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622879165","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622879165?lang=en_us&edition=fundamental","pubTime":"2026-03-28 00:37","pubTimestamp":1774629420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MTVA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 12:37 ET (16:37 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622994258","title":"MetaVia publishes investor presentation; outlines obesity and MASH pipeline, cash and cash equivalents $10.3 million as of Dec. 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2622994258","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622994258?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:41","pubTimestamp":1774557719,"startTime":"0","endTime":"0","summary":"MetaVia publishes investor presentation; outlines obesity and MASH pipeline, cash and cash equivalents $10.3 million as of Dec. 31, 2025. MetaVia outlined a cardiometabolic pipeline focused on obesity and metabolic dysfunction-associated steatohepatitis , highlighting DA-1726 and vanoglipel .For DA-1726, the company reported -9.1% body weight and -23.7% liver stiffness at Day 54 at a 48 mg dose.MetaVia said DA-1726 Phase 1 Part 3 is evaluating stepwise titration up to 64 mg, with data expected by YE 2026.For vanoglipel, MetaVia said a Phase 2a study in presumed MASH met its primary endpoint and reported ALT reduction of 22.8 U/L.MetaVia reported cash and cash equivalents of USD 10.3 million and no debt as of December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3Ynvsd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622893603","title":"MetaVia Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622893603","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622893603?lang=en_us&edition=fundamental","pubTime":"2026-03-27 02:43","pubTimestamp":1774550592,"startTime":"0","endTime":"0","summary":"MetaVia Inc reports results for the quarter ended December 31 - Earnings SummaryMetaVia Inc MTVA.OQ reported a quarterly adjusted loss of 42 cents per share for the quarter ended December 31, higher t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E289:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850154","title":"BRIEF-Metavia Reports Year End 2025 Financial Results And Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850154","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850154?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:49","pubTimestamp":1774529398,"startTime":"0","endTime":"0","summary":"BRIEF-Metavia Reports Year End 2025 Financial Results And Provides Corporate UpdateMetaVia Inc MTVA.O:METAVIA REPORTS YEAR END 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATESource text: ID:nPnbqN84TaFurther company coverage: MTVA.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA6WLVPB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850898","title":"MetaVia Q4 EPS $(0.42) Beats $(1.73) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850898","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850898?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:37","pubTimestamp":1774528623,"startTime":"0","endTime":"0","summary":"MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(1.73) by 75.69 percent. This is a 88.07 percent increase over losses of $(3.52) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51479543/metavia-q4-eps-0-42-beats-1-73-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MTVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622577768","title":"MetaVia FY2025 net loss narrows 53% to $13 million; R&D expenses drop 68% to $7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622577768","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622577768?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:32","pubTimestamp":1774528329,"startTime":"0","endTime":"0","summary":"MetaVia published a press release reporting year-end 2025 financial results and a corporate update.Net loss was USD 13.0 million, or USD 7.35 per share.Operating expenses were USD 13.7 million, down 52.42%.R&D expenses were USD 6.8 million, down 68.45%, primarily due to lower direct development spending on vanoglipel and DA-1726.Cash and cash equivalents were USD 10.3 million, down 35.84%, and management said year-end cash plus proceeds from a January 2026 public offering are expected to fund operations into the fourth quarter of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLbKWp89:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622084857","title":"Press Release: MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622084857","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622084857?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:31","pubTimestamp":1774528260,"startTime":"0","endTime":"0","summary":"48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit. Planned Phase 1 Part 3 16-Week Titration Study to Evaluate 48 mg  and 64 mg  Regimen Receives IRB Approval; Initiation Expected in April of 2026 with Data Anticipated in the Fourth Quarter. $10.3 Million in Cash and Cash Equivalents at End of Year and Proceeds From January 2026 Public Offering is Expected to Fund the Company Into the Fourth Quarter of 2026. CAMBRIDGE, Mass., March 26, 2026 /PRNewswire/ -- MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2025, and provided a corporate strategic update.Mr. Kim continued, \"Beyond DA-1726, we continued to advance vanoglipel , a novel G-Protein-Coupled Receptor 119  agonist, with the presentation of positive Phase 2a data at the American Association for the Study of Liver Dis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4022","BK4202","BK4181","MTVA","BK4218","OXM","PK","BK4139","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004697","title":"ADVISORY-Alert wrongly tagged to Metavia Inc withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004697?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:05","pubTimestamp":1774469122,"startTime":"0","endTime":"0","summary":"ADVISORY-Alert wrongly tagged to Metavia Inc withdrawnAn alert on Meta's response on the Los Angeles verdict was inadvertently tagged to Metavia Inc MTVA.O, an unrelated entity, and has been withdrawn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D11I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620739613","title":"MetaVia Inc  expected to post a loss of $1.24 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620739613","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620739613?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:08","pubTimestamp":1774012087,"startTime":"0","endTime":"0","summary":"MetaVia Inc  expected to post a loss of $1.24 a share - Earnings Preview MetaVia Inc MTVA.OQ MTVA.O is expected to  show no change in quarterly revenue when it reports  results on March 23 (estimated)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4081AQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620057265","title":"BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2620057265","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620057265?lang=en_us&edition=fundamental","pubTime":"2026-03-19 01:49","pubTimestamp":1773856151,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi TechnologiesWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning N","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL6N4060ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLG","SBUX","STZ","HL","CTMX","CDE","TTD","XYZ","OVID","SOFI","LEN","VRTX","WAL","NEM","LCID","GIS","RNXT","SABS","MTVA","PTGX","USEG","DUOL","NSPR","CRC","DOCU","BMRA","ABBV","APD","ARES","FICO","ARTL","TE","MMED","GEMI","ISRG","LNTH","SAIL","ORA","ARVN","KNX"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620549259","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2620549259","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620549259?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:11","pubTimestamp":1773839486,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, ProtagonistWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL6N4060JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBU","HL","PTGX","SABS","01698","WAL","MTVA","ICRC","ARTL","CF","NFLW","NEM","APD","DOCU","NBIL","TE","STZ","FICO","OVID","GEMI","MA","NFLP","SBUX","NFLY","ARVN","RNXT","CDE","XYZ","NEBX","NFXS","CRC","NWMX","CCUP","AU","GEMG","NEMG","IAUX","BMRA","TTD","NBIZ","TCHmain","SAIL","NBIG","SLG"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620517253","title":"BRIEF-Metavia Advances Glp-1-Based Obesity Program With Irb Approval For Higher-Dose Phase 1 Studies Of Da-1726, A Glp-1 And Glucagon Dual Agonist Demonstrating Best-In-Class Potential For Weight Loss And Glucose Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2620517253","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620517253?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:04","pubTimestamp":1773835469,"startTime":"0","endTime":"0","summary":"BRIEF-Metavia Advances Glp-1-Based Obesity Program With Irb Approval For Higher-Dose Phase 1 Studies Of Da-1726, A Glp-1 And Glucagon Dual Agonist Demonstrating Best-In-Class Potential For Weight Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nFWN4060PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253822","title":"MetaVia wins IRB approval for Phase 1 Part 3 trial of DA-1726 in obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253822","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253822?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:02","pubTimestamp":1773835321,"startTime":"0","endTime":"0","summary":"Metavia said an Institutional Review Board at Clinical Pharmacology of Miami approved its Phase 1 Part 3 trial of DA-1726, a GLP-1 and glucagon dual agonist. The trial plans to enroll 40 obese, otherwise healthy adults across two 16-week dose-titration cohorts. Part 3A will test 16 mg for 4 weeks followed by 48 mg for 12 weeks, while Part 3B will test 16 mg for 4 weeks followed by 32 mg for 4 weeks and 64 mg for 8 weeks.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire  on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL3h7Zqq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.metaviatx.com","stockEarnings":[{"period":"1week","weight":-0.0764},{"period":"1month","weight":0.0992},{"period":"3month","weight":-0.2692},{"period":"6month","weight":-0.8669},{"period":"1year","weight":-0.8225},{"period":"ytd","weight":-0.842}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.1098},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.0903},{"period":"1year","weight":0.3037},{"period":"ytd","weight":0.0728}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.000503},{"month":2,"riseRate":0.3,"avgChangeRate":0.007282},{"month":3,"riseRate":0.5,"avgChangeRate":-0.031121},{"month":4,"riseRate":0.4,"avgChangeRate":-0.109498},{"month":5,"riseRate":0.2,"avgChangeRate":-0.106003},{"month":6,"riseRate":0.555556,"avgChangeRate":0.090563},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.026489},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.189997},{"month":9,"riseRate":0.4,"avgChangeRate":0.065402},{"month":10,"riseRate":0.2,"avgChangeRate":-0.186131},{"month":11,"riseRate":0.3,"avgChangeRate":-0.112358},{"month":12,"riseRate":0.1,"avgChangeRate":-0.160075}],"exchange":"NASDAQ","name":"MetaVia Inc","nameEN":"MetaVia Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MetaVia Inc(MTVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MetaVia Inc,MTVA,MetaVia Inc股票,MetaVia Inc股票老虎,MetaVia Inc股票老虎国际,MetaVia Inc行情,MetaVia Inc股票行情,MetaVia Inc股价,MetaVia Inc股市,MetaVia Inc股票价格,MetaVia Inc股票交易,MetaVia Inc股票购买,MetaVia Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MetaVia Inc(MTVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MetaVia Inc(MTVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction